Blue Lake Biotechnology Secures $5 Million Grant for RSV Vaccine Trial
Blue Lake Biotechnology secured a $5 million grant to support its ongoing pediatric Phase 1/2a clinical trial of an intranasal RSV vaccine candidate.
Related stories
AIA Shares Hit 4-week High
AIA shares increased to 74.10 HKD, the highest since September 2026. Over the past 4 weeks, AIA Group gained 6.58%, and in the last 12 months, it decreased 2.25%.
L impact | EQUITY | Oct 30, 2026, 01:53 AM UTC
Japan’s Nikkei average down 3%
M impact | EQUITY | Oct 30, 2026, 01:53 AM UTC
Reddit Shares Plunge 18% After Revenue Outlook Misses Expectations
Reddit shares fell about 18% in after-hours trading in New York after the company said it would limit unregistered users’ access to its platform and issued a revenue outlook below
M impact | EQUITY | Oct 30, 2026, 01:51 AM UTC
Kingsgate Consolidated Reports Quarterly Gold and Silver Sales
Kingsgate Consolidated reported gold sales of 17,339 ounces and silver sales of 211,081 ounces for the quarter.
M impact | EQUITY | Oct 30, 2026, 01:46 AM UTC
Kingsgate Consolidated Produces 14,802 Ounces of Gold and 187,925 Ounces of Silver
The company reported an all-in sustaining cost of US$1,547 per ounce and said the metals were sold in the quarter.
L impact | EQUITY | Oct 30, 2026, 01:46 AM UTC
China’s Xinyi Sheng Drops 15.1% as Q3 Net Profit Falls
Xinyi Sheng shares fell as much as 15.1% Friday morning after its third-quarter net profit declined nearly one-fifth quarter over quarter.
M impact | EQUITY | Oct 30, 2026, 01:45 AM UTC